Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001
Selpercatinib is indicated for locally advanced/metastatic <i>RET</i>-activated solid tumors after progression or following prior systemic therapies. Until the recently published data from LIBRETTO-431 and LIBRETTO-531, there were limited effectiveness data comparing selpercatinib with o...
Main Authors: | Filippo De Braud, Barbara Deschler-Baier, John C. Morris, Francis Worden, Yimei Han, Urpo Kiiskinen, Min-Hua Jen, Scott S. Barker, Sylwia Szymczak, Adrienne M. Gilligan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/1/140 |
Similar Items
-
TRANSLATION TRANSFORMATIONS OF THE LIBRETTO BY N. TATE FOR THE OPERA “DIDO AND AENEAS”
by: Daniela V. Ustinova, et al.
Published: (2022-06-01) -
Beyond the libretto
by: Aleksandra Ożarowska
Published: (2021-11-01) -
Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
by: Tomoya Yokota
Published: (2022-09-01) -
Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
by: Paolo D. d'Arienzo, MD, MRCP, et al.
Published: (2023-12-01) -
Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report
by: Caio Abner Leite, et al.
Published: (2023-10-01)